mSEPT9 DNA Biomarker Test

About Hepion Pharmaceuticals

Hepion Pharmaceuticals is on a mission to redefine the early detection of hepatocellular carcinoma by delivering non-invasive, clinically grounded liquid biopsy solutions for patients at highest risk, particularly those with cirrhosis. The company's strategy involves advancing complementary biomarker platforms—methylated DNA (mSEPT9) and next-generation circulating tumor RNA (ctRNA)—with the goal of detecting HCC at its earliest, most treatable stages. Hepion is pursuing a disciplined path to value creation through CLIA deployment, FDA approval, and strategic partnerships, with the long-term vision of extending its diagnostic capabilities to other solid tumors where early detection remains a critical unmet need.

Therapeutic Areas